3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists

1. A compound of the formula (I);

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is selected from the group consisting of: H, aryl, alkyl, arylalkyl, cycloalkyl, and cycloalkylalkyl; optionally substituted with one or more substituents selected from the group consisting of:

a) H,

b) Halogen,

c) CF 3 ,

d) COR 13 ,

e) OH,

f) NR 13 R 14 ,

g) NO 2 ,

h) Cyano,

i) —Si(alkyl),

j) —Si(aryl),

k) SO 2 OR 13 ,

l) CO 2 R 13 ,

m) CONR 13 R 14 ,

n) SO 2 NR 13 R 14 ,

o) SO 2 R 13 ,

p) —OR 13 ,

r) —NR 13 R 14 ,

s) —O(C═O)R 13 ,

t) —O(C═O)NR 13 R 14 ,

u) —NR 13 COR 14 and

v) —NR 13 CO 2 R 14 ;

A is selected from the group consisting of:

wherein the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R 9 groups; and

B is

n is 0 to 6;

R 2 is selected from the group consisting of: hydrogen, OH, —C(O)OH, —SH, —SO 2 NR 13 R 14 , —NHC(O)R 13 , —NHSO 2 NR 13 R 14 , —NHSO 2 R 13 , —NR 13 R 14 , —C(O)NR 13 R 14 , —C(O)NHOR 13 , —C(O)NR 13 OH, —S(O 2 )OH, and —OC(O)R 13 ;

each R 3 and R 4 is independently selected from the group consisting of: hydrogen, cyano, halogen, alkyl, alkoxy, —OH, —CF 3 , —OCF 3 , —NO 2 , —C(O)R 13 , —C(O)OR 13 , —C(O)NHR 17 , —C(O)NR 13 R 14 , —SO (t) NR 13 R 14 , —SO (t) R 13 , —C(O)NR 13 OR 14 , unsubstituted or substituted aryl,

wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is selected from the group consisting of: R 9 groups;

each R 5 and R 6 are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, —CF 3 , —OCF 3 , —NO 2 , —C(O)R 13 , —C(O)OR 13 , —C(O)NR 13 R 14 , —SO (t) NR 13 R 14 , —C(O)NR 13 OR 14 , cyano, and unsubstituted or substituted aryl; wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of: R 9 groups;

each R 7 and R 8 is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, —CO 2 R 13 , —CONR 13 R 14 , alkynyl, alkenyl, and cycloalkenyl; and wherein there are one or more substituents on said substituted R 7 and R 8 groups, wherein each substituent is independently selected from the group consisting of:

a) halogen,

b) —CF 3 ,

c) —COR 13 ,

d) —OR 13 ,

e) —NR 13 R 14 ,

f) —NO 2 ,

g) —CN,

h) —SO 2 OR 13 ,

i) —Si(alkyl) 3 , wherein each alkyl is independently selected,

j) —Si(aryl) 3 , wherein each alkyl is independently selected,

k) —(R 13 ) 2 R 14 Si, wherein each R 13 is independently selected,

l) —CO 2 R 13 ,

m) —C(O)NR 13 R 14 ,

n) —SO 2 NR 13 R 14 ,

o) —SO 2 R 13 ,

p) —OC(O)R 13 ,

q) —OC(O)NR 13 R 14 ,

r) —NR 13 C(O)R 14 , and

s) —NR 13 CO 2 R 14 ;

each R 9 is independently selected from the group consisting of:

a) —R 13 ,

b) halogen,

c) —CF 3 ,

d) —COR 13 ,

e) —OR 13 ,

f) —NR 13 R 14 ,

g) —NO 2 ,

h) —CN,

i) —SO 2 R 13 ,

j) —SO 2 NR 13 R 14 ,

k) —NR 13 COR 14 ,

l) —CONR 13 R 14 ,

m) —NR 13 CO 2 R 14 ,

n) —CO 2 R 13 ,

o)

p) alkyl substituted with one or more —OH groups,

q) alkyl substituted with one or more —NR 13 R 14 group, and

r) —N(R 13 )SO 2 R 14 ;

each R 13 and R 14 is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein “heterocyloalkyl” means heterocyclic); wherein there are 1 to 6 substituents on said substituted R 13 and R 14 groups and each substituent is independently selected from the group consisting of: alkyl, —CF 3 , —OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R 40 ) 2 , —C(O)OR 15 , —C(O)NR 15 R 16 , —S(O) t NR 15 R 16 , —C(O)R 15 , —SO 2 R 15 provided that R 15 is not H, halogen, and —NHC(O)NR 15 R 16 ; or

R 13 and R 14 taken together with the nitrogen they are attached to in the groups —C(O)NR 13 R 14 and —SO 2 NR 13 R 14 form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR 18 ; wherein there are 1 to 3 substituents on the substituted cyclized R 13 and R 14 groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, —C(O)OR 15 , —C(O)NR 15 R 16 , —SO t NR 15 R 16 , —C(O)R 15 , —SO 2 R 15 provided that R 15 is not H, —NHC(O)NR 15 R 16 , —NHC(O)OR 15 , halogen, and a heterocycloalkenyl group;

each R 15 and R 16 is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl;

R 17 is selected from the group consisting of: —SO 2 alkyl, —SO 2 aryl, —SO 2 cycloalkyl, and —SO 2 heteroaryl;

R 18 is selected from the group consisting of: H, alkyl, aryl, heteroaryl, —C(O)R 19 , —SO 2 R 19 and —C(O)NR 19 R 20 ;

each R 19 and R 20 is independently selected from the group consisting of: alkyl, aryl and heteroaryl;

R 30 is selected from the group consisting of: alkyl, cycloalkyl, —CN, —NO 2 , or —SO 2 R 15 provided that R 15 not H;

each R 31 is independently selected from the group consisting of: unsubstituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl and unsubstituted or substituted cycloalkyl; wherein there are 1 to 6 substituents on said substituted R 31 groups and each substituent is independently selected from the group consisting of: alkyl, halogen and —CF 3 ;

each R 40 is independently selected from the group consisting of; H, alkyl and cycloalkyl; and

t is 0, 1 or 2.

2. The compound of claim 1 wherein A is selected from the group consisting of:

unsubstituted or substituted:

3. The compound of claim 1 wherein A is selected from the group consisting of:

4. The compound of claim 1 wherein A is selected from the group consisting of:

5. The compound of claim 1 wherein B is:

6. The compound of claim 1 wherein B is selected from the group consisting of:

7. The compound of claim 1 wherein B is

8. The compound of claim 1 wherein B is:

wherein R is—OH, and R 13 and R 14 are independently selected from the group consisting of H and alkyl.

9. The compound of claim 1 wherein R 1 is selected from the group consisting of: H, alkyl, aryl and cycloalkyl.

10. The compound of claim 1 wherein: R 1 is selected from H, methyl, phenyl and cyclohexyl.

11. The compound of claim 1 wherein

(1) substituent A in formula I is selected from the group consisting of:

wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: H, F, Cl, Br, alkyl, cycloalkyl, and —CF 3 ; R 7 is selected from the group consisting of: H, —CF 3 , —CF 2 CH 3 , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R 8 is H; and

(2)substituent B in formula I is:

wherein:

R 2 is selected from the group consisting of: H, OH, —NHC(O)R 13 and —NHSO 2 R 13 ;

R 4 is selected from the group consisting of: H, —NO 2 , cyano, —CH 3 or —CF 3 ;

R 5 is selected from the group consisting of: H, —CF 3 , —NO 2 , halogen and cyano;

R 6 is selected from the group consisting of: H, alkyl and —CF 3 ; and

each R 13 and R 14 is independently selected from the group coifisisting of: H, methyl, ethyl and isopropyl; or

R 13 and R 14 when taken together with the nitrogen they are attached to in the groups —NR 13 R 14 , —C(O)NR 13 R 14 , —SO 2 NR 13 R 14 , —OC(O)NR 13 R 14 , —CONR 13 R 14 , —NR 13 C(O)NR 13 R 14 , —SO t NR 13 R 14 , —NHSO 2 NR 13 R 14 form an unsubstituted or substituted saturated heterocyclic ring optionally having one additional heteroatom selected from O, S or NR 18 wherein R 18 is selected from H, alkyl, aryl, heteroaryl, —C(O)R 19 , —SO 2 R 19 and —C(O)NR 19 R 20 , wherein each R 19 and R 20 is independently selected from alkyl, aryl and heteroaryl, wherein there are 1 to 3 substituents on the substituted cyclized R 13 and R 14 groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, —C(O)OR 15 , —C(O)NR 15 R 16 , —SO t NR 15 R 16 , —C(O)R 15 , —SO 2 R 15 provided that R 15 is not H, —NHC(O)NR 15 R 16 and halogen; and wherein each R 15 and R 16 is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl.

12. The compound of claim 1 wherein:

(1) substituent A in formula I is selected from the group consisting of:

(2)substituent B in formula I is:

wherein:

R 2 is —OH;

R 4 is selected form the group consisting of: H, —CH 3 and —CF 3 ;

R 5 is selected from the group consisting of: H and cyano;

R 6 is selected from the group consisting of: H, —CH 3 and —CF 3 ; and

R 13 and R 14 are independently selected from the group consisting of H and methyl.

13. The compound of claim 1 wherein:

A is selected from:

B is

wherein,

R 2 is —OH;

R 3 is CONR 13 R 14 ;

R 4 is selected from the group consisting of H, CF 3 and CH 3 ;

R 5 is H and cyano;

R 6 is selected from the group consisting of H, CH 3 and CE 3 ;

R 13 and R 14 are methyl.

14. The compound of claim 1 selected from the group consisting of:

15. The compound of claim 1 selected from the group consisting of:

16. The compound of claim 1 having the formula:

17. The compound of claim 1 having the formula

18. The compound of claim 1 having the formula

19. The compound of claim 1 having the formula

20. The compound of claim 1 selected from the group consisting of:

21. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier therefor.